Epic Sciences

In the News


Epic, Avera ink deal to use liquid biopsy platform in clinical studies.

New York, GenomeWeb — Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.


Never leave a cell behind.

Rocky River, DDNews — Article covering Epic Sciences' platform technology and describes how it is being used in partnerships with outside research teams.


Utility of CTC platform in prostate cancer MDx.

New York, GenomeWeb — Epic Sciences was covered in a “Featured In-Depth” story in GenomeWeb Daily News: "Epic Sciences, MSKCC Research Suggests Utility for CTC Platform in Prostate Cancer MDx."


CAP accreditation of Epic Sciences lab.

San Diego, GenomeWeb — Epic Sciences has received accreditation from the College of American Pathologists (CAP). The CAP Laboratory Accreditation Program is recognized by the United States government as being equally or more stringent than the federal inspection program and is designed to specifically ensure the highest standard of care for all laboratory samples.


Oncology's future.

Xconomy — Article in Xconomy, by Murali Prahalad, Ph.D., president and CEO of Epic Sciences, looks forward, into oncology's future. The article discusses the intra- and inter- tumor diversity that is often found in cancer patients and what understanding this heterogeneity could mean for treatment.


Unbiased CTC detection and analysis from Epic Sciences.

San Diego, Epic Sciences — The Epic Sciences platform technology is designed to find CTCs from a tube of blood with millions of cells, is adaptable to multiple sample sources and can be customized to target a variety of different biomarkers. If you are trying to find one, we may be able to help you.


Diagnostics special report.

Rocky River, DDNews — Epic Sciences has been featured in a special report on liquid biopsy. This report discussed cancer as a heterogeneous disease and reviews sample choice in research and diagnostics.